Metabolica combines a point-of-care insulin biosensor with wearable biometric data and AI-powered analysis — giving clinicians a validated metabolic assessment at the point of care, for the first time.
Fasting insulin is the most sensitive early marker of metabolic dysfunction — measurably elevated years before glucose, HbA1c, or BMI become abnormal. Yet it is absent from every routine clinical blood panel in Australia.
The reason is practical: a standard insulin test requires a blood draw, cold-chain pathology logistics, and a 3–5 day laboratory turnaround. For the vast majority of clinical encounters, this makes routine insulin testing impossible.
Clinicians are managing the downstream consequences of metabolic dysfunction — type 2 diabetes, cardiovascular disease, metabolic syndrome — without ever seeing the upstream cause. Metabolica changes this.
Metabolica integrates components that have existed independently but have never been combined into a single validated clinical tool — until now.
A TGA-approved POC reader measures fasting insulin from a finger-prick blood sample in under 5 minutes at the point of care — no phlebotomist, no cold-chain, no laboratory delay.
TGA pathway activeContinuous glucose, HRV, sleep quality, and activity data pulled via secure API from 15+ wearable platforms — Garmin, Apple Health, Oura, Whoop, Dexcom, Fitbit and more.
15+ devicesCombined insulin and biometric data processed by a machine learning model trained on longitudinal metabolic health data — generating a personalised risk profile, updated in real time.
AI/ML predictionSecure, clinician-accessible web dashboard for remote patient monitoring, longitudinal trend analysis, and metabolic risk assessment. Integrates pathology results alongside POC and wearable data.
metabolica.appMetabolica is designed for deployment across four clinical and commercial channels — each generating data that makes the platform more powerful over time.
In-clinic point-of-care insulin testing and remote metabolic monitoring for at-risk patients. The practitioner channel provides the POC reader at zero upfront cost on a revenue-share model.
Perioperative metabolic risk assessment — insulin resistance as a modifiable surgical risk factor that is currently invisible in standard preoperative workups.
Objective workforce metabolic health baseline and evidence-based prevention program support. Tiered SaaS model for organisations of all sizes.
Population health monitoring for community sport clubs, regional health initiatives, Aboriginal health services, and chronic disease prevention programs. Grant-fundable channel.
Metabolica is a Margaret River-based clinical health technology platform developed by a team with over two decades of technology commercialisation experience. The platform is the product of postgraduate biomedical research combined with deep expertise in software engineering, financial management, and scaling technology products nationally.
Metabolica is at Innovation Maturity Level (IML) 3 — proof of concept demonstrated, with a working platform prototype at metabolica.app and confirmed hardware partnerships with commercial biosensor manufacturers. The platform is progressing through independent clinical validation to reach clinical deployment readiness.
Leading WA universities, medical research institutes, and data science organisations.
We welcome enquiries from clinicians, corporate wellness teams, research partners, and health investors. Tell us how you'd like to work with Metabolica.
Select the most relevant category and email us — we'll respond within one business day.